Table 2.
Gene Sets | LNCAP | Prostate Adenocarcinoma | ||||||
---|---|---|---|---|---|---|---|---|
Number | ES | p-value | FDR | Number | ES | p-value | FDR | |
Arginine and Proline Metabolism | 17 (49) | −0.38 | 0 | 0.11 | 14 (52) | −0.31 | 0.53 | 0.94 |
Ascorbate and Aldarate Metabolism | 11 (18) | −0.61 | 0 | 0.18 | 8 (16) | −0.61 | 0.21 | 1.00 |
Histidine Metabolism | 12 (27) | −0.42 | 0 | 0.13 | 5 (28) | −0.24 | 0.88 | 0.97 |
Nicotinate and Nicotinamide Metabolism | 8 (21) | −0.33 | 0 | 0.15 | 7 (22) | −0.28 | 0.83 | 0.99 |
Pentose and Glucuronate Interconversions | 7 (20) | −0.54 | 0 | 0.17 | 8 (18) | −0.63 | 0.14 | 1.00 |
Pentose Phosphate Pathway | 9 (25) | −0.36 | 0 | 0.10 | 18 (26) | −0.20 | 0.97 | 0.98 |
Phenylalanine Metabolism | 10 (18) | −0.49 | 0 | 0.12 | 6 (18) | −0.40 | 0.50 | 0.99 |
Retinol Metabolism | 17 (48) | −0.48 | 0 | 0.10 | 20 (54) | −0.42 | 0.59 | 0.98 |
Starch and Sucrose Metabolism | 13 (41) | −0.41 | 0 | 0.10 | 8 (43) | −0.38 | 0.47 | 0.97 |
Tyrosine Metabolism | 14 (38) | −0.52 | 0 | 0.10 | 13 (42) | −0.40 | 0.40 | 0.99 |
Butanoate Metabolism | 10 (30) | −0.41 | 0.09 | 0.13 | 8 (34) | −0.39 | 0.29 | 0.95 |
Glycine Serine and Threonine Metabolism | 12 (29) | −0.40 | 0.10 | 0.18 | 4 (31) | −0.31 | 0.76 | 1.00 |
Tryptophan Metabolism | 15 (37) | −0.34 | 0.10 | 0.30 | 8 (39) | −0.27 | 0.81 | 0.97 |
Valine Leucine and Isoleucine Degradation | 20 (44) | −0.31 | 0.30 | 0.33 | 12 (44) | −0.35 | 0.31 | 0.99 |
Amino Sugar and Nucleotide Sugar Metabolism | 14 (43) | −0.22 | 0.31 | 0.42 | 18 (44) | −0.33 | 0.40 | 0.99 |
Note: Number: number of genes contributing to the leading-edge subset within the gene set (number of genes in the gene set after filtering out these genes not in the expression dataset); ES: enrichment score; p-value: nominal p-value not adjusted for gene set size or multiple hypothesis testing; a p-value of zero (0) indicates an actual p-value of less than 0.001; and FDR: false discovery rate.